Development of a Prophylactic Ebola Vaccine Using an Heterologous Prime-Boost Regimen: Phase II - Sofia ref.: 115861

Project Information

EBOVAC2

Grant agreement ID: 115861

DOI

10.3030/115861

Project closed

EC signature date 6 March 2015

Start date 1 December 2014

End date 31 May 2021

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost

€ 50 710 893,00

EU contribution

€ 22 790 820,00

Coordinated by

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Deliverables

Documents, reports (3)

Ebola project clustering activity plan

Migration

Capacity-building programme

Migration

Capacity-building implementation report

Migration

Other (2)

Communication tools

Migration

1st EBOVAC2 e-newsletter

Migration

Publications

Peer reviewed articles (4)

Durable natural killer cell responses after heterologous two-dose Ebola vaccination

Author(s): Helen R. Wagstaffe, Giada Susannini, Rodolphe Thiébaut, Laura Richert, Yves Lévy, Viki Bockstal, Jeroen N. Stoop, Kerstin Luhn, Macaya Douoguih, Eleanor M. Riley, Christine Lacabaratz, Martin R. Goodier
Published in: npj Vaccines, Issue 6/1, 2021, ISSN 2059-0105
Publisher: Nature Partners Journal
DOI: 10.1038/s41541-021-00280-0

Antibody-Dependent Natural Killer Cell Activation After Ebola Vaccination

Author(s): Helen R Wagstaffe, Elizabeth A Clutterbuck, Viki Bockstal, Jeroen N Stoop, Kerstin Luhn, Macaya Douoguih, Georgi Shukarev, Matthew D Snape, Andrew J Pollard, Eleanor M Riley, Martin R Goodier
Published in: The Journal of Infectious Diseases, Issue 223/7, 2019, Page(s) 1171-1182, ISSN 0022-1899
Publisher: University of Chicago Press
DOI: 10.1093/infdis/jiz657

Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial

Author(s): Andrew J Pollard, Odile Launay, Jean-Daniel Lelievre, Christine Lacabaratz, Sophie Grande, Neil Goldstein, Cynthia Robinson, Auguste Gaddah, Viki Bockstal, Aurelie Wiedemann, Maarten Leyssen, Kerstin Luhn, Laura Richert, Christine Bétard, Malick M Gibani, Elizabeth A Clutterbuck, Matthew D Snape, Yves Levy, Macaya Douoguih, Rodolphe Thiebaut, Christopher McShane, Benoit Callendret, Stephanie Dinc
Published in: The Lancet Infectious Diseases, Issue 21/4, 2021, Page(s) 493-506, ISSN 1473-3099
Publisher: The Lancet Publishing Group
DOI: 10.1016/s1473-3099(20)30476-x

Ebola virus glycoprotein stimulates IL-18–dependent natural killer cell responses

Author(s): Helen R. Wagstaffe, Elizabeth A. Clutterbuck, Viki Bockstal, Jeroen N. Stoop, Kerstin Luhn, Macaya Douoguih, Georgi Shukarev, Matthew D. Snape, Andrew J. Pollard, Eleanor M. Riley, Martin R. Goodier
Published in: Journal of Clinical Investigation, Issue 130/7, 2020, Page(s) 3936-3946, ISSN 0021-9738
Publisher: American Society for Clinical Investigation
DOI: 10.1172/jci132438

Conference proceedings (1)

1-Barrières et facilitateurs de la mise en oeuvre d’un essai vaccinal en situation d’urgence: cas de l’essai EBOVAC2 au Burkina Faso. 2- Barriers and facilitators in implementin g a vaccine trial in emergency situation: the case of EBOLA Vaccine Phase II Trial (VAC52150 EBL2002) in Burkina Faso

Author(s): Barry H, Valéa I, Berthé A, Lougué G, Tinto H, Thiébaut R, et al.
Published in: Issue 3-6 may 2016; 26 to 28 May 2016., 2016
Publisher: n/a